Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of glucagon-like peptide-1 receptor agonists on outcomes in knee osteoarthritis among persons with obesity has not been well studied. METHODS We conducted a 68-week, double-blind, randomized, placebo-controlled trial at 61 sites in 11 countries. Participants with obesity (a body-mass index [BMI; the weight in kilograms divided by the square of the height in meters] of ≥30) and a clinical and radiologic diagnosis of moderate knee osteoarthritis with at least moderate pain were randomly assigned, in a 2:1 ratio, to receive once-weekly subcutaneous semaglutide (2.4 mg) or placebo, in addition to counseling on physical activity and a reduced-calorie diet. The primary end points were the percentage change in body weight and the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score (on a scale of 0 to 100, with higher scores reflecting worse outcomes) from baseline to week 68. A key confirmatory secondary end point was the physical-function score on the 36-Item Short Form Health Survey (SF-36), version 2 (on a scale of 0 to 100, with higher scores indicating greater well-being). RESULTS A total of 407 participants were enrolled. The mean age was 56 years, the mean BMI 40.3, and the mean WOMAC pain score 70.9. A total of 81.6% of the participants were women. The mean change in body weight from baseline to week 68 was -13…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Semaglutide (2•4 mg/week) has been shown to cause symptomatic improvement related to moderate knee osteoarthritis as well as bodyweight reduction.89”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [89]
In the citing paper
“In a 68-week clinical trial involving individuals with obesity and knee osteoarthritis with moderate to severe pain (STEP-9), semaglutide treatment led to a greater reduction in the Western Ontario and McMaster Universities Osteoarthritis Index score (–41.7 points) as compared with placebo (–27.5 points) (88).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [88]
In the citing paper
“While the contribution of weight loss remains unclear, this study, alongside emerging preclinical data from rodent models, suggests that GLP-1 medicines may offer efficacy in inflammation-driven diseases independent of the amelioration of metabolic dysfunction.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [88]
In the citing paper
“In the STEP-9 trial, use of semaglutide led to greater weight loss and improvements in knee pain and physical function compared to placebo in patients with obesity and moderate-to-severe osteoarthritis-related symptoms.45”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [45]
In the citing paper
“In the STEP 9 trial involving adults with obesity and knee osteoarthritis, semaglutide resulted in significantly greater weight loss (− 13.7% vs. −3.2%), pain reduction (WOMAC − 41.7 vs. −27.5 points), and improvement in physical function (SF-36 + 12.0 vs. +6.5 points) compared to placebo (all P < 0.001) at 68 weeks, with a similar rate of serious adverse events [63].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [63]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Altman, R., Asch, E., Bloch, D., Bole, G., Borenstein, D., Brandt, K., Christy, W., Cooke, T. D., Greenwald, R., Hochberg, M., et al. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780290816 · Cited by 6,777
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationHunter, D. J., & Bierma-Zeinstra, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30417-9 · Cited by 4,795
OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis
Bannuru, R. R., Osani, M. C., Vaysbrot, E. E., Arden, N. K., Bennell, K., Bierma-Zeinstra, S. M. A., Kraus, V. B., Lohmander, L. S., Abbott, J. H., Bhandari, M., et al. (2019) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2019.06.011 · Cited by 3,542
Kolasinski, S. L., Neogi, T., Hochberg, M. C., Oatis, C., Guyatt, G., Block, J., Callahan, L., Copenhaver, C., Dodge, C., Felson, D., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24131 · Cited by 2,516
Classifications in Brief: Kellgren-Lawrence Classification of Osteoarthritis
Kohn, M. D., Sassoon, A. A., & Fernando, N. D. (2016) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-016-4732-4 · Cited by 1,459
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 301–400 of 438
Intra-articular GLP-1 analogues: A new disease-modifying strategy for osteoarthritis?
Berenbaum, F. (2026) · Joint Bone Spine · doi:10.1016/j.jbspin.2026.106045
Midlife weight gain: challenges and solutions
Hung, S., & Adams, K. E. (2026) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001093 · Cited by 1
Supervía, M., de Murieta, E. S., Figueroa, J., Arroyo-Riaño, M. O., de Munain, M. L. L., de Miguel, C., Laxe, S., Marco, E., & Morata, A. B. (2026) · Rehabilitación · doi:10.1016/j.rh.2026.100968
Surgical and nonsurgical treatment of hip and knee osteoarthritis: a 2026 perspective
Laigaard, J. H., Maleitzke, T., Skou, S. T., Mechlenburg, I., Bandholm, T., Berg, L. C., & Overgaard, S. (2026) · Acta Orthopaedica · doi:10.2340/17453674.2026.45570
Hung, T.-H., Chen, C.-R., Hsu, C., Carvalho, A. F., Stubbs, B., Tseng, P., Wang, L., & Lin, P. (2026) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70041
How Somatic Mutations cause Aging without Causing AgingPreprint
Wolf, A. M. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6431458
Treatment options for patients with advanced osteoarthritis who decline knee surgery
Kacprzak, J., Kołaczyński, R., Surma, A., Sokalski, D., Adamus, J. P., Pulik, Ł., & Łęgosz, P. (2026) · World Journal of Orthopedics · doi:10.5312/wjo.v17.i4.114991 · Cited by 1
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
“Finally, in patients with obesity and osteoarthritis, administration of semaglutide 2.4 mg/week reduced the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score and improved the physical function score [51].”
InfluentialZhou, X., Liang, H., Liu, H., Sun, M., & Cai, Z. (2026) · Medical Gas Research · doi:10.4103/mgr.medgasres-d-25-00147
“Mautner et al. 28 conducted a multicenter, randomized controlled trial comparing the safety and efficacy of autologous bone marrow aspirate concentrate, autologous adipose-derived stromal vascular fraction, and allogeneic human umbilical cord-derived mesenchymal stromal cell injections with…”
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
White, M. S., Kogan, F., Delp, S. L., Chu, C. R., Sherman, S. L., Anoosha Pai, S., Gold, G. E., Chaudhari, A. S., & Gatti, A. A. (2026) · Osteoarthritis and Cartilage · doi:10.64898/2026.04.15.26350819 · Cited by 1
“In practice, this supports the use of weight-loss[37] strategies, including lifestyle interventions targeting diet and exercise[38] and, where appropriate, Glucagon-like peptide-1 (GLP-1) based pharmacotherapies,[39, 40] as potential structural risk-modifying approaches for KOA.”
Cho, D. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0002
“35) By alleviating the burden of PAD and osteoarthritis, NuSH therapies may break the vicious cycle of immobility, facilitating the physical rehabilitation essential for holistic HF management.”
Santos, M. D. S., Costa, F. R., Protásio, J., Santos, G. S., Martins, R. A., Pires, L., Kruel, A., Azzini, G. O. M., & Lana, J. F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093749 · Cited by 1
“Bliddal and colleagues demonstrated in a randomized controlled trial that once-weekly semaglutide improved pain, function, and reduced inflammation and bodyweight in patients with knee osteoarthritis and obesity [141].”
Antiobesity Medications and Endoscopic Bariatric Therapies: A Narrative Review
Frankl, L., Kim, L. N., & Popov, V. (2026) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2026.250976
Rivera, N., Bradley, T., Cottrill, E. J., Ray, E. J., Zachem, T. J., Crowell, K., Goodwin, C. R., & Erickson, M. M. (2026) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000002064 · Cited by 1
Ortiz‐Prado, E., Vasconez-Gonzalez, J., Izquierdo‐Condoy, J. S., & López-Jaramillo, P. A. (2026) · doi:10.2196/preprints.99738
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
McCormick, N. P., de Moura, C. S., Zhang, J., Holladay, E. E., Xie, F., Mehta, T. S., Baker, J. F., & Curtis, J. R. (2026) · ACR Open Rheumatology · doi:10.1002/acr2.90068
“35 Given the well-established links between obesity, disease activity, and treatment response in RMDs, our fi ndings underscore the therapeutic relevance of weight management using GLP-1 RAs in these populations, with potential implications for improving long-term outcomes.”
Qualitative Indicator Report Analysis Based on SAS Software Statistical Technology
Zhang, X. (2026) · Lecture notes in networks and systems · doi:10.1007/978-3-032-21013-5_3
Moyal, J., & Rehany, B. (2026) · University of Toronto Medical Journal · doi:10.33137/utmj.v103i2.46711
Khursheed, S., Mukhtar, T., Nazeem, A., Shaban, M., & Ahmad, K. (2026) · The Healer Journal of Physiotherapy and Rehabilitation Sciences · doi:10.55735/v3zbx612
Luo, J., Chen, X., Chen, N., Li, Y., Zhao, L., Cui, J., & Liu, X. (2026) · RMD Open · doi:10.1136/rmdopen-2026-006881 · Cited by 1
Implications of GLP-1 RA Therapy on Skeletal Health and Orthopedics: A Commentary
Gertzulin, M., & Drake, M. T. (2026) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1177/15563316261450988
Oxysterol undersulfation promotes osteoarthritis by fueling chondrocyte lipid accumulation
Wang, H., Ni, B., Qian, Y., Ding, G., He, T., Zhang, X., Xu, H., Hao, X., Hu, Y., Wang, D., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73322-7
Benedict, B. C., White-Gilliam, D., Pradhan, A., Yakdan, S. M., Hammo, A., Budd, L., Arkam, F., Tang, S. Y., Schechtman, K. B., Cheng, A. L., et al. (2026) · medRxiv · doi:10.64898/2026.05.20.26353666
Trampert, D. C. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.05.008
Altés, A., Moreno, Ó., Sastre-Belío, M., Rodríguez-Urgellés, E., Pérez-Alcántara, F., Larsen, S., Martín‐Lorenzo, A., Sandín, M., & Vidal, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03644-x
“…drug with evidence of reduced risk of cardiovascular (CV) death, all‑cause mortality, stroke and myocardial infarction (MI) [48], and has shown improvement in complications such as HF with preserved ejection fraction, prediabe‑ tes, osteoarthritis and metabolic steatohepatitis [40, 47, 50, 52].”
Dual amylin and calcitonin receptor agonists as multifaceted disease-modifying osteoarthritis drugs
Mohamed, K., Larsen, A. T., Thudium, C. S., Bezerra, A. B. G., Karsdal, M. A., Bay‐Jensen, A., & Henriksen, K. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02124-0
“On the other hand, the recently completed STEP-9 trial demonstrated that weight loss resulted in clinically meaningful reductions in knee pain [12].”
InfluentialWeight loss in hip and knee osteoarthritis
Ladefoged, M. R., Aljuboori, S. M. S., Bjerre-Bastos, J. J., Bliddal, H., & Overgaard, S. (2026) · Ugeskrift for Læger · doi:10.61409/v09250729 · Cited by 1
Self-citationZarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“In the STEP-9 trial, semaglutide was associated with improvements in knee pain and physical function compared with placebo in patients with obesity and moderate-to-severe knee osteoarthritis, in parallel with substantial weight loss [165, 166].”
Adiposopathy-Based Chronic Diseases and Therapeutic Role of Semaglutide
Tiwari, A., Pahuja, V., Vipin, V. P., Erande, S. G., Indurkar, S. A., Kumar, A., Saha, I., Lahiri, K. D., Kishore, R., Alok, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_21_26
Mehta, P., Yang, M., Kharouf, F., Abarza, V. C., Gao, S., Cook, R. J., Gladman, D. D., Chandran, V., & Poddubnyy, D. (2026) · Rheumatology · doi:10.1093/rheumatology/keag303 · Cited by 4
Beyond Weight Loss: The Musculoskeletal Effects of GLP-1 Therapies
Zurowska, A. (2026) · EMJ Rheumatology · doi:10.33590/emjrheumatol/771475ds
Wu, J., Lei, Y., Sa, R., Zhong, Y., & Lu, Y. J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1856307 · Cited by 1
Qian, Z., Li, S., Yu-yang, L., Min‐lin, L., Huang, C., Min-hui, L., We, L., & Si-yuan, T. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118172 · Cited by 1
Frier, K. C., Dietl, M., Aronson, S., Dhani, J. S., James, K., Betensky, D. J., Selzer, F., Losina, E., Katz, J. N., Kim, J. S., et al. (2026) · ACR Open Rheumatology · doi:10.1002/acr2.90070
McCann, C. J., Clement, N., Murray, A. D., Kearney, R., Madigan, S. M., Gee, C. W., Walmsley, P., Morrison, S. R., Chopra, S., & Hall, A. J. (2026) · British Journal of Sports Medicine · doi:10.1136/bjsports-2025-111225 · Cited by 1
“29 In comparison, the most effective conventional intervention (combined psychological, dietary and exercise strategies) identified in a recent network meta-analysis achieved approximately 7 kg weight loss.”
InfluentialJacobsen, L., Viana, D. P. D. C., Folador, G. M., Schor, E., & Invitti, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135678
“Randomized clinical trials have demonstrated reductions in pain-related outcomes in idiopathic intracranial hypertension treated with exenatide [59] and in knee osteoarthritis treated with semaglutide [60].”
Patel, S. V., Derwin, K. A., Li, X., Apte, S., & Piuzzi, N. S. (2026) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2026.05.002 · Cited by 1
Kim, S., Barthel, A., Smurzynski, M., & MacEwan, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71033
FORRESTER, T. D., Meyers, J., Hitchens, A., & Perez‐Nieves, M. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100293
“Recent clinical trials for incretins have shown promising results in reduction of both body weight and OA knee pain [24 – 26].”
Pan, S., Weng, C., Sheen, Y., Tsai, S.-F., Lin, J., Chen, J., Lin, C., Huang, S.-P., Chang, C.-J., Lin, H.-J., et al. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.06.023 · Cited by 1
Lau, L. C., Lui, T. W. D., Wen, C., Zhu, L., Lin, S., Leung, T. K. C., Luk, M. H., Ping Keung, C. H. A. N., Cheung, A., Chiu, K. Y., et al. (2026) · Bone & Joint Open · doi:10.1302/2633-1462.77.bjo-2025-0359.r1
“26 However, the STEP9 trial’s participants had a mean age of 56 years (SD 10) and a mean BMI of 40.3 kg/m 2 (SD 7.2); only 5.4% participants were Asians and it was not reported whether these participants subsequently had TKA or not and their outcomes.”
InfluentialShu, T., Shang, X., & Zhou, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1871461 · Cited by 1
“Epidemiological data also support an association between GLP-1 receptor agonist use and a reduced risk of OA progression, strongly bolstered by a recent randomized controlled trial demonstrating the ef fi cacy of semaglutide in knee OA patients (43).”
A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications
Chao, A. M., Asante, R., Sersah, M. E., Jahangir, U. A., Peary, A., & Kudaya, D. Q. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70162
Intensive diet or knee arthroplasty for severe knee osteoarthritis: The inka randomised trial
Henriksen, M., Christensen, R., Poulsen, A. S., Bunyoz, K. I., Aljuboori, S. M. S., Nielsen, C. T., Haugegaard, T., Gudbergsen, H., Gromov, K., Døssing, A., et al. (2026) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2026.07.004 · Cited by 1
Self-citationChai, R., Liu, J., Hu, L., & Zheng, P. (2026) · Translational research · doi:10.1016/j.trsl.2026.07.003
Xue, C., Kui, W., Li, X., Li, L., Song, L., Mao, D., Speakman, J. R., Qin, L., Tong, L., & Chen, D. (2026) · Life Medicine · doi:10.1093/lifemedi/lnag029
Chen, Q., Chen, Y., Zhang, H., & Zhang, B. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-08309-2
Metabolic Syndrome: Redefine and Expand Its Reach, Yet Preserve Its Clinical Value
Saad, M. J. A., Santos, A., Geloneze, B., & Velloso, L. A. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.07.008 · Cited by 1
Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction
Vignera, S. L., & Condorelli, R. A. (2026) · Biomedicines · doi:10.3390/biomedicines14071644 · Cited by 1
“Obesity is a major risk factor for knee OA, contributing through both mechanical loading and metabolic/inflammatory mechanisms [107].”
Trudeau, M., Schaffer, O., & Schwarzkopf, R. M. (2026) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2026.05.004
Cartilage regeneration: clinical progress and future outlook
Thomas-Charles, C. A., Xue, R., Agosto, A. R., Farkash, A. F., Kindblom, P., Lo, Y. L. E., Lo, K. W. ‐., & Li, Y. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.06.017
GLP-1 receptor agonists in obesity and musculoskeletal disease
Biddle, K., Galloway, J. B., & Bechman, K. (2026) · Medicine · doi:10.1016/j.mpmed.2026.06.004
Malviya, V. (2026) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2026.00050
Hyung, S., Park, U. J., Ryu, J. H., & Chung, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15155932
“In adults with obesity and knee osteoarthritis with at least moderate pain, once-weekly semaglutide 2.4 mg plus lifestyle counseling produced greater reductions in body weight and WOMAC pain than placebo plus lifestyle counseling over 68 weeks; physical function also improved [15].”
InfluentialRen, L., Xiao, Y., Liu, X., Liu, L., Ma, K., Zhang, C., & Zhang, C. (2026) · The Innovation Medicine · doi:10.59717/j.xinn-med.2026.100244
Ziegler, D., Kempler, P., Bala, C. G., Mankovsky, B., Schnell, O., Spallone, V., Stirban, A. O., & Tesfaye, S. H. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02241-w · Cited by 3
“Likewise, the percentages of responders with ≥ 50% pain reduction were 65% for semaglutide vs 35% for placebo (number needed to treat: 3.3) [90].”
InfluentialMa, Y.-X., Lin, M., Nan, Y., Li, N.-N., Liu, B., Wang, H., Ning, S.-Y., & Zhang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1889437 · Cited by 3
“The STEP 9 phase III randomized controlled trial provided direct clinical evidence: in patients with concurrent obesity and knee osteoarthritis, 68-week semaglutide treatment produced concurrent and signi fi cant improvements in body weight and knee WOMAC scores (8).”
InfluentialChangement dans la prise en charge de l’obésité : vision du clinicien
Montastier, É. (2026) · Biologie Aujourd hui · doi:10.1051/jbio/2026002
Weisman, A., & Masharawi, Y. (2026) · Journal of Pain · doi:10.1016/j.jpain.2026.106399
Chae, K., Jones, M. R., Yang, A., Ghosh, J., Rajagopal, S., & Chao, A. M. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc26-0062
Merriwether, E. N., Maqsood, M. N., Vanegas, S. M., Em, S. T., Perez, N., Parikh, M., Ruiz-Guerenabarrena, B., Humala-Martinez, C., Lopez, B., Fillingim, R. B., et al. (2026) · medRxiv · doi:10.64898/2026.08.04.26359660
Palka, W., Moćko, P., Śladowska, K., Holko, P., & Kawalec, P. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03006-y
Potential underutilisation of weight loss medications in obese patients with knee osteoarthritis
Badhe, N., Busby, C., Kurien, T., & Marson, B. A. (2026) · Annals of The Royal College of Surgeons of England · doi:10.1308/rcsann.2026.0063
Hashmi, A., Scott, S., Jung, M., Saunders, F. R., Ebsim, R., Gregory, J. S., Arbeeva, L. S., Nelson, A. E., Harvey, N. C., Lindner, C., et al. (2026) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2026.07.013 · Cited by 2
Hang, W., Triantafilou, K., & Zhou, Y. (2026) · Current Rheumatology Reports · doi:10.1007/s11926-026-01229-9 · Cited by 1
“Weight loss through diet and exercise slowed cartilage breakdown in high-BMI patients [ 8 ], and the STEP trial showed that semaglutide reduced both structural damage and symptoms specifically in patients with obesity and knee OA [ 89 ].”
Assessing, diagnosing, and managing hip osteoarthritis in primary care
Hoveidaei, A. H., Al‐Obaedi, O., Arvin, A., Johnston, B., & Ravi, B. (2026) · BMJ · doi:10.1136/bmj-2026-258168
Hobai, I. A., & Goodin, B. (2026) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000008227
Recenti, F., Kiadaliri, A., Battista, S., Hellberg, C., Englund, M., Testa, M., & Dell’Isola, A. (2026) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2026.100860
“Promising pharmacological strategies, such as GLP-1 receptor agonists, have shown benefits in OA with obesity-related phenotypes and may represent a disease-modifying alternative to opioids [43].”
Canecki-Varžić, S., Bilić-Čurčić, I., Bakula, M., Bulum, T., Naglić, M. Č., Delić-Brkljačić, D., Wensveen, T. T., Vitković, D. F., Jurišić‐Eržen, D., Klobučar, S., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1834323 · Cited by 1
Min, L., You, Y., Ren, S., & Chen, C. (2026) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70368
“Osteoarthritis (OA), the most prevalent musculoskeletal disorder, affects over 528 million individuals globally, posing a significant public health challenge due to limited disease-modifying therapeutic options (Bliddal et al. 2024; Cao et al. 2024).”
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
A rheumatological reading of GLP-1 receptor agonists: from muscle loss to musculoskeletal gain
Ciaffi, J., D’Amuri, A., Caporali, R., & Ursini, F. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02204-1
Papastathopoulou, N. S., Neri, S., Assirelli, E., D’Amuri, A., Greco, S., Ciaffi, J., & Ursini, F. (2026) · Rheumatology Advances in Practice · doi:10.1093/rap/rkag105
Chen, L. (2026) · Aging Medicine and Healthcare · doi:10.4103/amah.amah.v17-3_editorial
Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)
Rosero, R., Tamayo, M., Henao, D. C., Polanco, J. P., David, C., Alba, J. C., Valeria, G., Camilo, C., Eder, H., Ricardo, C., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70209
Retuerto, M., Fernández, I. G., Ramos, M. A., Fernández, I. G., Blanco, A. V., Sanz, A. M., Rivero-Lezcano, O. M., & Díez‐Álvarez, E. (2026) · RMD Open · doi:10.1136/rmdopen-2026-007122
“14 Our findings address a specific gap regarding real-world metabolic responses in rheumatology practice and the potential influence of chronic inflammation, although definitive conclusions require larger studies.”
From adiposity to multisystem morbidity: the case for weight loss as disease modification
Sattar, N. A., Ferguson, L. D., & Lee, M. M. Y. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00186-5
Milluzzo, A., Oteri, V., Manuella, L., Pulvirenti, A., & Frittitta, L. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02189-x
He, Y., Gao, J., Liu, Y., Wu, S., Kuang, J., Chen, D., Xu, B., Zhang, M., & Fang, Q. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111163
Prospects for the use of new antidiabetic drugs in rheumatology
Nasonov, E. L., Shestakova, M. V., Kondratyeva, L. V., & Елисеев, М. С. (2026) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2026-315-334 · Cited by 1
Wang, M., Li, M., Yang, S., Zhang, H., & Liu, P. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/3238847
Expert Consensus on the Management of Obesity in Older Adults (2026 Edition)
Pan, Q., & Guo, L. (2026) · Aging Medicine · doi:10.1002/agm2.70105
“In one study ( n = 271; mean age, 56 years), semaglutide 2.4 mg for 68 weeks reduced body weight, significantly relieved obesity-related knee osteo-arthritis pain, and improved ADL [73].”
InfluentialComputational Platforms for Membrane-Active Peptide Therapeutic Design
Zan, B., Chen, C. H., Sabha, M., Wu, K., Kadri, M., Nwajiaku, O. L., Hoogland, D., Ulmschneider, J. P., & Ulmschneider, M. B. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.6c00100
Sun, K., Wu, Y.-G., Xiang, Y.-H., Li, M.-Y., Ding, Y., Zhang, L.-S., Zeng, Y., Xie, H.-Q., & Shen, B. (2026) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x261485407
“62,63 However, more interventional studies are needed to determine whether modifying these metabolic profiles can prevent OA progression.”
Davis, S. C., Patel, S. V., Fletcher, S., McLaughlin, J. P., Deren, M. E., & Piuzzi, N. S. (2026) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.21203/rs.3.rs-10744245/v1 · Cited by 1
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
Conaghan, P. G., Rolland, C., Frampton, J., Lavoie, L., Giblin, K., Robinson, R., & Perez‐Nieves, M. (2026) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2026.100875
“In the recent phase 3 STEP 9 study (NCT05064735), semaglutide alleviated knee pain in patients with KOA and obesity [76].”
Glp-1 receptor agonists in obesity: Current evidence and clinical outcomes
Vidal, J. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.009
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025 · Cited by 1
Смена парадигмы лечения сахарного диабета 2-го типа – от метаболической коррекции к органопротекции
Мохорт, Т. В. (2026) · Кардиология в Беларуси · doi:10.34883/pi.2026.18.3.009
Lu, D., Li, N., Yuan, Z., & Gao, Y. (2026) · Clinical Obesity · doi:10.1111/cob.70112
Wang, Y., Fan, X., Gao, J., Xing, L., & Tian, F. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00761-0 · Cited by 1
Benedict, B. C., White-Gilliam, D., Pradhan, A., Yakdan, S. M., Hammo, A., Budd, L., Arkam, F., Tang, S. Y., Schechtman, K. B., Cheng, A. L., et al. (2026) · Pain Medicine · doi:10.1093/pm/pnag121
Majanović, S. K., Belančić, A., Gkrinia, E. M. M., Božek, T., Štimac, I., & Ciudin, A. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102141
Economic evaluations of antiobesity medications: A systematic literature review
Jurković, M., Fajkić, A., Faour, A. K., Momčilović, M., Turčić, P., & Belančić, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70825
Rombach, J., Hannani, M. T., Henriksen, K., Bihlet, A. R., Bajaj, M., He, Y., Bay-Jensen, A.-C., Thudium, C. S., & Karsdal, M. (2026) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2026.09.007
Weight management in cardiology practice: challenges and opportunities
Leening, M. J. G., Martens, F. M. A. C., & Hemels, M. E. W. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02075-1
“…symptoms or outcomes in over-weight or obese patients with type 2 diabetes [11], chronic kidney disease [14], metabolic dysfunction-associated steatotic liver disease [15, 16], obstructive sleep apnea [17], knee osteoarthritis [18], and heart failure with preserved ejection fraction [19, 20].”
Odonkor, C. A., Dodurgali, M. R., Cox, F. R., Klimov, I. J., & Abd-Elsayed, A. A. (2026) · Nutrients · doi:10.3390/nu18193120
“Against this, the divergence between the positive STEP 9 trial (large weight loss, pain benefit) and the negative liraglutide trial (modest weight loss, no pain benefit) indicates that, at least for musculoskeletal pain, the magnitude of weight loss matters [68,69].”
Influential
Metadata
- Authors
- Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., Wizert, A., & Kristensen, L. E.
- Affiliations
- University of Louisville (US)
- From the Parker Institute, Copenhagen University Hospital at Bispebjerg and Frederiksberg, Copenhagen (H. Bliddal, L.E.K.), and Novo Nordisk, Søborg (T.H.M., A.K., J.S.N., A.W.) — both in Denmark; Louisville Metabolic and Atherosclerosis Research Center, University of Louisville School of Medicine, Louisville, KY (H. Bays); the Department of Nutrition, Hôpital Européen Georges Pompidou, Assistance Publique–Hôpitaux de Paris, Université Paris Cité, Paris (S.C.); the Obesity Department, Capio St. Göran’s Hospital, and Medical Department at the Karolinska Institute, Stockholm (J.U.H.); the Department of Endocrinology, Obesity, and Nutrition, Vestfold Hospital Trust, Tønsberg, and the Department of Endocrinology, Morbid Obesity, and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, Oslo — both in Norway (J.H.); Centro de Investigación en Reumatología y Especialidades Médicas, Bogota, Colombia (P.V.S.); and the University of Toronto and York University, Toronto, McMaster University, Hamil...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-31
- Volume
- 391
- Issue
- 17
- Pages
- 1573-1583
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4403912607
- Cited by
- 440
- References
- 37
- Citations by year
- 2026: 235 · 2025: 197 · 2024: 8
- FWCI
- 141.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
- Keywords
- semaglutide, knee osteoarthritis, obesity, GLP-1 receptor agonists, weight loss, osteoarthritis pain, physical function, hypocaloric diet, physical activity counseling, adverse events, serious adverse events, drug safety, quality of life, Western Ontario and McMaster Universities Osteoarthritis Index, SF-36
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Combined Modality Therapy, Counseling, Double-Blind Method, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Pain Measurement, Weight Loss, Body Mass Index, Arthralgia, Osteoarthritis, Knee, Caloric Restriction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.